EMA Authorised: Ryeqo (relugolix;norethisterone acetate;estradiol hemihydrate) — Gedeon Richter Plc.

View source ↗

Summary

EMA authorised Ryeqo, a combination therapy for leiomyoma, developed by Gedeon Richter Plc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyoma

Drugs mentioned

• Ryeqo (relugolix; norethisterone acetate; estradiol hemihydrate)

Snippet

Status: Authorised. Therapeutic area: Leiomyoma. MAH: Gedeon Richter Plc.. Decision date: 18/01/2024